Voyager Therapeutics, Inc. VYGR 深 滬
等待開盤 04-02 09:30:00 美东时间
3.99
+0.130
+3.37%
華盛通- 最 高4.09
- 今 開3.89
- 成交量 50.80万股
- 最 低 3.89
- 昨 收 3.86
- 總市值 2.38亿
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.645
- 委 比 18.02%
- 總股本 5959.94万
- 歷史最高 31.91
- 量 比 1.00
- 振 幅 5.18%
- 歷史最低 2.46
- 每 手 1
- 風險率 0.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
03-18 01:35
美股牛股 | VYGR飙升21%，Q4亏损收窄及销售额超预期；Figure大涨超20%
VYGR飙升21%，Q4亏损收窄及销售额超预期；Figure大涨超20%，进军汽车贷款市场获华尔街唱多；Stagwell涨逾17%，引入AppLovin先进的移动广告平台>>
03-11 16:04
Voyager Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
Voyager Therapeutics shares are trading higher after the company reported bette...
03-11 00:26
Earnings Breakdown: Voyager Therapeutics Q4
Voyager Therapeutics (NASDAQ:VYGR) released its Q4 earnings on Monday, March 9,...
03-10 04:04
Voyager Therapeutics Q4 EPS $(0.46) Beats $(0.54) Estimate, Sales $15.336M Beat $10.491M Estimate
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.54) by 14.66 percent. This is a 22.03 percent increase over losses of $(0.59) per share
03-10 04:03
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported its fourth quarter and full year 2025 financial and operating results, highlighting a transformative year for tau-targeting therapies for Alzheimer's disease (AD) in 2026, with anticipated clinical data for VY1706 and VY7523, entry of IV-delivered neuro gene therapies into the clinic, and advancements in their Voyager NeuroShuttle™ platform. The company ended 2025 with a cash position of $202 million, sufficient to s...
03-09 20:01
Voyager Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil
Voyager Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil Voyager Therapeutics Inc. wird am 10. März 2026 an der Leerink Global Healthcare Conference 2026 in Miami, FL, teilnehmen. Weitere Informationen sind auf der Website von Voyager Therapeutics verfügbar: http://www.voyag
02-09 21:01
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in five upcoming investor conferences in 2026, including fireside chats at Guggenheim Emerging Outlook: Biotech Summit on Feb 11, Oppenheimer Healthcare Life Sciences Conference on Feb 26, TD Cowen Health Care Conference on Mar 2, Leerink Global Healthcare Conference on Mar 10, and Stifel CNS Days on Mar 18. A webcast of the Oppenheimer event will be accessible on the company’s website.voyagerthera...
02-09 13:00
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.
2025-11-26 01:22
